Exosome Diagnostics and Therapeutics Market
Number of pages: 100 | Report Format: PDF | Published date: 02 February, 2023
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
|
Report Attribute |
Details |
|
Market size value in 2021 |
US$ 98 million |
|
Revenue forecast in 2030 |
US$ 1.56 billion |
|
Growth Rate |
CAGR of 36% from 2022 to 2030 |
|
Base year for estimation |
2021 |
|
Forecast period |
2022-2030 |
|
Historical Year |
2020 |
|
Segments covered |
Product Type, Application, End User, and Region. |
|
Regional scope |
North America, Europe, Asia Pacific, and the Rest of the World (ROW) |
The global exosome diagnostics and therapeutics devices market is valued at US$ 98 million in 2021. It is expected to witness a CAGR of 36% during the forecast period from 2022 to 2030.
Market Fundamentals
Exosomes are extracellular vesicles produced by cells, which contain metabolites, proteins, lipids, and nucleic acids. They influence different facets of cell biology and act as intermediaries of close and far intercellular communication in health and illness. Applications of exosomes are linked to immunological responses, viral pathogenicity, pregnancy, cardiovascular illnesses, diseases of the central nervous system, and cancer development. Exosomes effectively transfer biomolecules, such as proteins, metabolites, and nucleic acids, into target cells to change their biological response. Exosomes are made to carry a range of therapeutic payloads, such as short-interfering RNAs (RNAs), immunological modulators, antisense oligonucleotides, chemotherapeutic medicines, and immunological agents. Exosome vesicle-based liquid biopsy may be used to diagnose individuals with cancer and other disorders, and to predict their prognosis modulators that may target their distribution to a specific area.
Exosomes act as intercellular messengers, have distinctive payloads, are highly prevalent in almost all biofluids, and have high biological stability. Therefore, it was only natural to investigate their potential as biomarkers in liquid biopsy. Exosomes' involvement in specific diseases, like chronic obstructive pulmonary disease, lends more evidence to their usefulness as biomarkers. Exosomes also have diagnostic value outside of the cancer field; these include pain, autoimmune diseases, and hypertensive disorders of pregnancy.
Exosomes are increasingly being recognized as potential therapies due to their capacity to incite strong cellular responses both in vitro and in vivo. Exosomes, made up of cellular membranes with several sticky proteins on their surface, are known to be particularly adept at facilitating cell-cell contact and offer a unique method for delivering diverse therapeutic drugs to target cells. Exosomes are becoming recognized increasingly as novel modulators for various therapeutic uses, including immunization, biological targeting agents, and drug delivery systems. Therapeutic exosome systems can be broadly divided into two categories: artificial exosomes and naive exosomes: Therapeutic exosomes, called naive exosomes, come from non-engineered cells that produce them. Artificial exosomes are therapeutic, either generated in vitro after isolation or derived from altered-producing cells.
[6363463]
Market Dynamics
The growth in the prevalence of chronic diseases, infectious diseases, autoimmune diseases, and cancer, as well as the rise in demand for molecular diagnosis, are the main factors driving the exosome diagnostic and therapeutic market share. Additionally, continuous advancements in drug development and discovery in exosome technologies provide important insights into biological heterogeneity and function and improve our capacity to harness the therapeutic and diagnostic potential for infectious disease and cancer. Therefore, the development of the exosome diagnostic and therapeutic markets is fueled by technological improvement in the healthcare industry. The capacity of exosome technologies as diagnostic and therapeutic tools are used to treat various diseases, such as neurodegeneration, cardiovascular dysfunction, and cancer. This has led to an increase in the demand for drug therapies and a surge in R&D activities in the pharmaceutical and biopharmaceutical fields. Exosomes may one day be used to diagnose cancer, and the advancement of translational precision medicine will boost their usage in diagnostic and therapeutic procedures, spurring the development of the exosome diagnostic and therapeutic markets.
Exosome product approval and commercialization laws are strict, which may impede the industry's expansion over the forecasted period. In addition, the increase over the research period can be hampered by technological issues related to using exosomes in various applications. The lack of effective transfection techniques and the requirement for method tuning are two main obstacles. These difficulties are projected to hamper market expansion.
The global exosome diagnostics and therapeutics market has been analyzed from four perspectives: Product Type, Application, End User, and Region.
Exosome Diagnostics and Therapeutics Market by Product Type
[3563622]
Based on product type, the global exosome diagnostics and therapeutics market has been subdivided into kits & reagents, instruments, and services & software. The kits & reagents segment accounts for the biggest revenue share in the global exosome diagnostics and therapeutics market. Extracellular vesicle isolation can be a laborious, challenging, and non-specific technique. As a result, leading companies are releasing cutting-edge kits and reagents to expand the uses of exosomes, driving the segment's expansion.
Exosome Diagnostics and Therapeutics Market by Application
Based on application, the global exosome diagnostics and therapeutics market has been divided into cancer, cardiovascular diseases, infectious diseases, and others. Due to the wide range of uses for exosomes in cancer diagnosis, prognosis, and therapy, the cancer application sector led the global exosome diagnostics and therapeutics market. Nano-sized membrane vesicles called cancer-related exosomes significantly impact the tumor microenvironment. New research suggests that exosomes can carry specific payloads, including proteins and nucleic acids indicative of the state of tumors. Exosomes are therefore utilized as prognostic and diagnostic indicators for various malignancies.
Exosome Diagnostics And Therapeutics Devices Market by End User
Based on end users, the global exosome diagnostics and therapeutics devices market has been divided into pharmaceutical & biotechnology companies, hospitals & diagnostic centers, cancer institutes. During the projection period, the hospitals sector is anticipated to grow at a higher CAGR and account for a significant market share. High-end technical goods and the wide availability of instruments and reagents are predicted to fuel segment market expansion. In addition, increased cancer rates, the need for immunizations, and highly qualified medical experts in hospitals help hospitals make money. Favorable reimbursement schemes are further increasing the need for hospitals for hospital procedures and upgrades to healthcare facilities.
Exosome Diagnostics And Therapeutics Devices Market by Region
Based on region, the global exosome diagnostics and therapeutics market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World. With a large revenue share, the U.S. dominates the North America market, and it is anticipated that it will continue to develop rapidly over the projection period. Germany showed Y-O-Y growth in the Western European exosome diagnostic and therapeutic market in 2021. By the end of 2030, it is anticipated to possess a larger market value share. The growth is linked to the Germany’s growing focus on exosome applications for accessing stem cells' therapeutic effects in research operations. The increased cancer incidence in Germany and the need for sophisticated diagnostic tests were the main drivers of this growth.
China is expected to develop at a profitable pace during the forecast period and controls most of the market share in the Asia Pacific region in 2021. The rise of clinically investigated and observed exosome applications is attributed to China’s expanding exosome diagnostic and therapeutic business. Due to an increase in cancer cases worldwide and the desire for enhanced diagnostic technologies for the disease, the global growth of the exosomes diagnostic and therapeutics market is anticipated to increase substantially.
Competitive Landscape
Some prominent players operating in the global exosome diagnostics and therapeutics market are:
Strategic Developments
The global exosome diagnostics and therapeutics market is expected to grow at a CAGR of 36% in the forecast period from 2022 to 2030.
Codiak Biosciences, Danaher Corp., Fujifilm Holdings Corp., Lonza Group AG, and Miltenyi Biotec are key players in the global exosome diagnostics and therapeutics market.
The kits and reagents segment dominates the global exosome diagnostics and therapeutics market.
Asia Pacific region is expected to witness the highest global exosome diagnostics and therapeutics market growth in the forecast period.
The global exosome diagnostics and therapeutics market was valued at US$ 98 million in 2021.
*Insights on financial performance are subject to the availability of information in the public domain
Using the fundamental research and knowledge services capabilities of GRG Health, Growth Plus Reports may now be tailored based on client needs.
GRG Health's unique GrowthMIX strategy and comprehensive research methodology enable us to provide unique and valuable insights to our clients while uncovering trends that would not be discovered using traditional techniques.
Snehal Deshmukh
Principle Consultant
Speak to analyst